Ruoyi Biotech

Executive Summary

Ruoyi Biotech is a private Chinese biopharmaceutical company founded in 2018, headquartered in Shanghai, focused on developing innovative monoclonal antibodies for oncology. The company leverages advanced antibody engineering to create targeted therapies for solid tumors and hematological cancers, addressing significant unmet medical needs in China and globally. Currently in Phase 1 clinical stage with 50-200 employees, Ruoyi Biotech has not disclosed total funding or valuation. The early-stage pipeline and limited public information introduce uncertainty, but the company's specialization in antibody engineering and targeting of high-need oncology indications provide a basis for potential value creation if clinical data are positive. Key upcoming catalysts are the completion of ongoing Phase 1 trials, potential IND submissions for new candidates, and possible strategic partnerships to support further development and commercialization.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 Data Readout for Lead Monoclonal Antibody Candidate55% success
• Q4 2026IND Filing for Next-Generation Antibody Program60% success
• H1 2027Strategic Partnership or Licensing Deal with Global Pharma40% success